Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775869 | 0.82 | LMNA (0.39) | HRH4HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL1776644 | 0.82 | LMNA (0.39) | HRH4HTR2ADRD3 | |
| SCHEMBL1775987 | 0.82 | HTT (0.39) | ALDH1A1MAPTHTTHTR2A | |
| Hydrochloric Acid SCHEMBL1774418 | 0.81 | HTT (0.39) | ALDH1A1MAPTHTTHTR2A | |
| SCHEMBL1776120 | 0.78 | KIT (0.39) | MAPTDRD2HTR2ADRD3 | |
| SCHEMBL1775433 | 0.78 | HTR6 (0.40) | DRD2HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL1775562 | 0.77 | KIT (0.38) | MAPTDRD2HTR2ADRD3 | |
| SCHEMBL5012492 | 0.77 | HRH4 (0.40) | HRH4CHIADRD2HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL1775559 | 0.77 | ALDH1A1 (0.35) | HRH4ALDH1A1DRD2HTR2ADRD3 | |
| SCHEMBL1776299 | 0.75 | TDP1 (0.44) | ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101081845-A | Substituted sulphone and sulphonamide compounds useful for the treatment of obesity, type II diabetes and cns disorders | BIOVITRUM AB (SE) | 2007-12-05 | — | — | CN | claimed |
| CN-1662521-A | Novel compounds useful for the treatment of obesity, type II diabetes and CNS disorders | BIOVITRUM AB (SE) | 2005-08-31 | — | — | CN | claimed |
| US-7943639-B2 | Such as 6-benzenesulfonyl-4-piperazin-1-yl-quinoline hydrochloride; for treatment of central nervous system and/or 5- HT6 receptor related disorders; for weight gain/loss | PROXIMAGEN LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| CN-101081845-A | Substituted sulphone and sulphonamide compounds useful for the treatment of obesity, type II diabetes and cns disorders | BIOVITRUM AB (SE) | 2007-12-05 | — | — | CN | disclosed |
| CN-1907982-A | New compounds useful for the treatment of obesity,type II diabetes and CNS disorders | BIOVITRUM AB (SE) | 2007-02-07 | — | — | CN | disclosed |
| CN-1662521-A | Novel compounds useful for the treatment of obesity, type II diabetes and CNS disorders | BIOVITRUM AB (SE) | 2005-08-31 | — | — | CN | disclosed |